Page 130 - A Magyar Szemorvostársaság 2023. évi kongresszusa - Tudományos program és előadáskivonatok
P. 130
Results: 430 patients (age: mean 67.2 years [22–91 years]) were randomized. Clinical non-
inferiority of NET/LAT to BIM/TIM was demonstrated in the intention-to-treat population
(NET/LAT–BIM/TIM ≤ 1.5 mmHg at all 9 time points and ≤ 1.0 mmHg at 6 of 9 time points at
Week 2, Week 6, and Month3). Mean IOP reduction ranged from –9.94 to –9.03 mmHg for
NET/LAT and –10.41 to –8.45 mmHg for BIM/TIM. Ocular treatment-emergent adverse events
(TEAs) with NET/LAT and BIM/TIM were mild or moderate: conjunctival hyperemia (30.7% vs.
9.0%), cornea verticillata (11.0% vs. 0.0%), eye pruritus (7.8% vs. 0.9%) and punctate keratitis
(5.5% vs. 1.9%). No serious TEAEs were reported.
Conclusion: NET/LAT was non-inferior to BIM/TIM in patients with POAG and OHT and
provided efficacious reduction of IOP over 6 months. NET/LAT was associated with more TEAs
than BIM/TIM but it was generally well tolerated.
